Hengrui Pharmaceutical announced that the company and its subsidiaries have received the “Drug Clinical Trial Approval Notice” for HRS-7172 tablets, adbelizumab injections, SHR-4610 injections, SHR-8068 injections, SHR-9839 injections, injectable SHR-1826, bevacizumab injections, HRS-4642 injections, HRS-6093 tablets, and HRS-7058 capsules approved and issued by the State Drug Administration and will conduct clinical trials in the near future. The above drugs cover types such as anti-tumor small molecule inhibitors, monoclonal antibodies, and antibody-conjugated drugs. Many of these are innovative drugs developed independently, and some drug-related projects have advanced to phase III clinical stage. The drug will need to complete clinical trials and pass review and approval before it can be marketed. There is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.